Jacobs Levy Equity Management
KLRS

Jacobs Levy Equity Management’s Kalaris Therapeutics KLRS Stock Holding History

Jacobs Levy Equity Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-28,888
Closed -$279K – 1226
2024
Q4 		$279K Buy
+28,888
New +$437K ﹤0.01% 877

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management's KLRS Position: Q1 2025 in Review

Jacobs Levy Equity Management sold out of Kalaris Therapeutics (KLRS) in Q1 2025, closing a stake of 28,888 shares — an estimated $279K sold.

Jacobs Levy Equity Management first reported a position in KLRS in Q4 2024 and held it in 1 quarter. The position peaked at $279K in Q4 2024. 32 funds tracked by Wall St. Rank hold KLRS as of Q1 2025.

  • Jacobs Levy Equity Management reported no remaining Kalaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 28,888 Kalaris Therapeutics shares in Q1 2025, an estimated $279K.
  • Jacobs Levy Equity Management first reported a position in Kalaris Therapeutics in Q4 2024 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Kalaris Therapeutics position peaked at $279K in Q4 2024.
  • 32 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2025, filed 15 May 2025.